Opthea announces Investor Day with insights on sozinibercept for wet AMD, featuring expert presentations in January and February 2025.
Quiver AI Summary
Opthea Limited announced it will host an Investor Day on January 28, 2025, in New York City, where the company will provide updates on its lead product candidate, sozinibercept, aimed at treating wet age-related macular degeneration (wet AMD). This event comes ahead of the expected topline data readouts from two pivotal trials, COAST and ShORe, scheduled for early and mid-2025, respectively. The presentations will feature insights from Dr. Charles C. Wykoff and Opthea's Chief Commercial Officer Mike Campbell, focusing on the need for improved vision outcomes and the commercial readiness for sozinibercept, particularly in combination with existing treatments. Further in-person presentations are planned in Sydney and Melbourne in early February. The company aims to demonstrate sozinibercept's potential to enhance patient outcomes in wet AMD.
Potential Positives
- Opthea is hosting an Investor Day in New York City, showcasing its commitment to transparency and engagement with investors as it prepares for pivotal trial data on sozinibercept.
- The presence of international retina expert Dr. Charles C. Wykoff at the Investor Day adds credibility to the event and highlights the expertise behind Opthea’s research and development efforts.
- The company emphasizes the commercial potential of sozinibercept, indicating readiness for market entry and addressing significant medical needs in treating wet AMD.
- Opthea’s Chief Commercial Officer, Mike Campbell, has extensive experience in launching and commercializing successful retinal therapies, which may enhance investor confidence in the company’s strategies.
Potential Negatives
- Announcement of a pivotal data readout expected in mid-2025 may indicate delays or uncertainties in the development timeline of sozinibercept, raising concerns among investors about the speed of progress.
- Opthea’s reliance on the upcoming clinical trials for its lead product candidate, sozinibercept, may create pressure for a successful outcome, which could impact the company's valuation and investor confidence if results are unfavorable.
- The necessity for an Investor Day indicates that the company may need to actively seek investor support, potentially highlighting existing challenges in gaining market confidence and demonstrating commercial viability.
FAQ
What is the date and location of Opthea's Investor Day event?
Opthea's Investor Day will be held on January 28, 2025, in New York City at 1:30 PM ET.
Who will present at the Investor Day event?
The event will feature presentations from Dr. Charles C. Wykoff and Opthea's senior management team, including Mike Campbell.
What is sozinibercept and its significance?
Sozinibercept is Opthea's lead candidate aimed at transforming treatment for wet AMD, providing superior vision gains.
When are the additional presentations in Sydney and Melbourne scheduled?
Presentations in Sydney will occur on February 3 and in Melbourne on February 5, both at 4:30 PM AEDT.
Will there be a live webcast of the New York event?
Yes, the New York event will have a live webcast, and a replay will be available on Opthea's website afterward.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$OPT Hedge Fund Activity
We have seen 4 institutional investors add shares of $OPT stock to their portfolio, and 6 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- VICTORY CAPITAL MANAGEMENT INC removed 840,040 shares (-100.0%) from their portfolio in Q3 2024
- TEACHER RETIREMENT SYSTEM OF TEXAS removed 269,399 shares (-100.0%) from their portfolio in Q3 2024
- BANK OF MONTREAL /CAN/ removed 48,618 shares (-100.0%) from their portfolio in Q3 2024
- JANE STREET GROUP, LLC added 26,632 shares (+inf%) to their portfolio in Q3 2024
- TWIN LAKES CAPITAL MANAGEMENT, LLC added 19,806 shares (+inf%) to their portfolio in Q3 2024
- ROYAL BANK OF CANADA removed 6,000 shares (-100.0%) from their portfolio in Q3 2024
- MILLENNIUM MANAGEMENT LLC removed 3,777 shares (-5.3%) from their portfolio in Q3 2024
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
Updates on
commercial insights and readiness plans for sozinibercept in wet AMD
Opthea management to present in New York City on Tuesday, January 28 at 1:30 PM ET
In-person events in Sydney on February 3 and Melbourne on February 5
MELBOURNE, Australia and PRINCETON, N.J., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ:OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that it will host an Investor Day on Tuesday, January 28, 2025 at 1:30 PM ET in New York City, followed by presentations in Sydney and Melbourne in early February.
As the Company prepares for the anticipated topline data readout of its two pivotal trials, COAST in early CY Q2 2025 and ShORe in mid-CY 2025, the New York in-person event and live webcast will feature presentations from international retina thought leader
Charles C. Wykoff, MD, PhD
and Opthea’s senior management team, including Chief Commercial Officer
Mike Campbell.
Opthea’s Investor Day will highlight the following:
The continued medical need for better vision outcomes in wet AMD and the opportunity for sozinibercept to transform patient lives with superior vision gains.
New insights on the commercial potential and commercial readiness plans for sozinibercept in combination with standard-of-care anti-VEGF-A therapies.
It is expected that the presentations, followed by a question-and-answer session, will conclude by approximately 3:00 PM ET. Following the live webcast, a replay will be made available on the Company’s website.
The Company’s senior management will also host in-person investor presentations in Sydney on Monday February 3 at 4:30 PM AEDT and Melbourne on Wednesday February 5 at 4:30 PM AEDT.
Links to register or access the webcast will be available on the Investor Section of the Company’s website under “Events and Presentations”
here
.
About Charles C. Wykoff, MD, PhD
Charles C. Wykoff, MD, PhD is a board-certified retina specialist with Retina Consultants of Texas (RCTX). Leading a top international research facility for vitreoretinal diseases, Dr. Wykoff serves as Director of Research at RCTX and is Chair of Research and Clinical Trials at Retina Consultants of America. In addition, he serves as the elected Deputy Chair of Ophthalmology for the Blanton Eye Institute, Houston Methodist Hospital, and Clinical Professor of Ophthalmology, Weill Cornell Medical College. Dr. Wykoff has been awarded multiple Achievement, Honor and Senior Honor Awards and has published over 350 peer-reviewed manuscripts. Dr. Wykoff serves as the Chief Investigator for Opthea’s COAST Phase 3 pivotal trial and is Co-Chair of the COAST and ShORe Steering Committee.
About Mike Campbell, Chief Commercial Officer, Opthea
Mr. Campbell brings 30 years of biotech and pharmaceutical commercial leadership experience across sales, marketing, market access, patient services, and operations to the Company. He dedicated most of his career to launching and commercializing innovative treatments for retinal and ocular surface diseases. During his tenure at Genentech, Mr. Campbell was a key leader for the commercial build and launch of Lucentis
®
, the first anti-VEGF-A treatment approved for wet AMD; he served in commercial leadership roles through the lifecycle of Lucentis
®,
including the expansion into Diabetic Macula Edema, and Retinal Vein Occlusion. He also contributed to the pre-launch commercial planning of Beovu
®
in wet AMD at Novartis, as well as the $3.4 billion divestiture of Xiidra
®
for Dry Eye Disease to Novartis, during his tenure at Shire. Mr. Campbell most recently served as Senior Vice President and Head of Commercial at Viatris Eye Care which acquired Oyster Point Pharma, where he led the commercial build for the launch of Tyrvaya
®
in Dry Eye Disease. Mr. Campbell holds a Bachelor of Science degree from Auburn University and is an Executive Education graduate from the University of Pennsylvania, Wharton School of Business.
About Opthea
Opthea (ASX/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to address the unmet needs in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).
Opthea’s lead product candidate, sozinibercept, is being evaluated in two fully enrolled pivotal Phase 3 clinical trials (COAST,
NCT04757636
, and ShORe,
NCT04757610
) for use in combination with standard-of-care anti-VEGF-A therapies to improve overall efficacy and deliver superior vision gains compared to standard-of-care anti-VEGF-A agents alone.
To learn more, visit our website at
www.opthea.com
and follow us on
X
and
LinkedIn
.
Authorized for release to ASX by Frederic Guerard, PharmD, CEO
Investor Inquiries PJ Kelleher LifeSci Advisors, LLC Email: pkelleher@lifesciadvisors.com Phone: 617-430-7579 | Media Inquiries Silvana Guerci-Lena NorthStream Global Partners Email: silvana@nsgpllc.com |
Join our email database to receive program updates:
Tel: +61 (0) 3 9826 0399, Email:
info@opthea.com
Web:
www.opthea.com
Source: Opthea Limited
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
